Tag: meningococcal vaccines market outlook

  • 2024-2033 Meningococcal Vaccines Market Forecast: Predicted Growth Rate and Market Size

    2024-2033 Meningococcal Vaccines Market Forecast: Predicted Growth Rate and Market Size

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    How Rapidly is the Meningococcal Vaccines Market Forecasted to Grow Between 2024 and 2033?

    The market size for meningococcal vaccines has seen a swift expansion in recent times. The projection is that it will increase from $3.57 billion in 2023 to $3.94 billion in 2024, with a compound annual growth rate (CAGR) of 10.5%. Factors such as disease prevalence, international travel behavior, the state of healthcare facilities, readiness for epidemics, and the extent of health insurance coverage account for the growth witnessed during the historical period.

    The market for meningococcal vaccines is projected to experience considerable expansion in the coming years. It is estimated to reach $5.69 billion by 2028, growing at a compound annual growth rate (CAGR) of 9.6%. The surge during the prediction period can be linked to the emergence of novel strains, intensifying globalization, escalating healthcare investment, health campaigns, and evolving regulatory frameworks. Predominant trends during this projected period encompass individualized vaccines, digitized vaccination records, gene alteration technologies, multi-valent vaccines, and subscription-driven vaccine models.

    Claim Your Free Sample of the Global Meningococcal Vaccines Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

    What Factors Are Behind the Rapid Growth of the meningococcal vaccines Market?

    Expected growth in the health care sector’s spending is all set to spearhead the expansion of the meningococcal vaccine market. The term healthcare encompasses residential care institutes, nursing facilities as well as intermediate care establishments for persons dealing with mental health issues and cognitive disabilities. The escalating costs of newer vaccine generations relative to their antecedents has evolved into a prime issue in debates regarding the appropriateness of the higher prices of the new vaccines against the benefits they confer. The comprehensive evaluation of the socio-economic impacts of immunization is gradually gaining prominence in the research field dedicated to assessing the value of vaccination. A notable example is a May 2022 article by the American Medical Association, a US professional association and lobbying group comprising physicians and medical students. It reported a 9.7% surge in the US healthcare expenses reaching $4.1 trillion, or $12,530 per person. Remarkably, this growth rate significantly surpasses the rate seen in 2019, which was 4.3%. Consequently, the surge in healthcare spending is greatly contributing to the growth of the meningococcal vaccine market.

    What Are the Principal Segments of the Meningococcal Vaccines Market?

    1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

    2) By Serotype: Men Acwy, Men B/Bc, Men C

    3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

    4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

    5) By End user: Hospitals, Research, Academic Institutes

    What Emerging Patterns Are Redefining the Meningococcal Vaccines Market?

    Order Now for Fast Delivery of Your Meningococcal Vaccines Market Report!

    https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

    Which Geographical Regions Are Shaping the Meningococcal Vaccines Market Growth?

    North America was the largest region in the meningococcal vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Meningococcal Vaccines Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the meningococcal vaccines market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Meningococcal Vaccines Market Include

    1. Meningococcal Vaccines Market Executive Summary

    2. Meningococcal Vaccines Market Segments

    3. Meningococcal Vaccines Market Size And Template Market Growth Rate

    4. Key Meningococcal Vaccines Market Trends

    5. Major Meningococcal Vaccines Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Meningococcal Vaccines Market

    26. Top Meningococcal Vaccines Companies

    27. Meningococcal Vaccines Market Opportunities And Strategies

    28. Meningococcal Vaccines Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    DTP Vaccines Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

    Veterinary Vaccines Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

    Companion Animal Veterinary Vaccines Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • What Is The Forecast Growth Rate For The Meningococcal Vaccines Market?

    What Is The Forecast Growth Rate For The Meningococcal Vaccines Market?

    The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

    The meningococcal vaccines market has seen rapid expansion in recent years, driven by various factors such as increased disease incidence, global travel trends, and improved healthcare infrastructure. This blog delves into the current market landscape, future projections, and significant trends shaping the market.

    Current Market Landscape

    • Market Size: The meningococcal vaccines market was valued at $3.57 billion in 2023.
    • Growth Rate: Expected to reach $3.94 billion in 2024, growing at a compound annual growth rate (CAGR) of 10.5%.

    Key Growth Drivers

    Disease Incidence and Global Travel

    • Rising cases of meningococcal disease worldwide.
    • Increased global travel heightens the risk of disease spread.

    Healthcare Infrastructure and Epidemic Preparedness

    • Strengthened healthcare infrastructure supports broader vaccine distribution.
    • Preparedness for potential epidemics fuels vaccine demand.

    Health Insurance Coverage

    • Improved health insurance coverage facilitates greater vaccine accessibility.

    Read More On The Meningococcal Vaccines Market Report 2024 – https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

    Future Projections

    • Market Size: Projected to grow to $5.69 billion by 2028.
    • Growth Rate: Expected CAGR of 9.6%.

    Factors Driving Future Growth

    Emergence of New Strains and Globalization

    • New meningococcal strains necessitate updated vaccines.
    • Increasing globalization further spreads disease risks.

    Healthcare Investments and Health Initiatives

    • Growing investments in healthcare enhance vaccine development and distribution.
    • Initiatives promoting vaccination improve public health outcomes.

    Regulatory Landscape

    • Evolving regulations support the introduction of new vaccines.

    Emerging Trends

    • Personalized Vaccines: Tailored vaccines to improve efficacy and safety.
    • Digital Vaccination Records: Streamlined tracking of vaccination status.
    • Gene Editing Technologies: Advanced methods for developing effective vaccines.
    • Multi-valent Vaccines: Vaccines targeting multiple serogroups.
    • Subscription-Based Models: Innovative payment models for vaccine access.

    Impact of Rising Healthcare Spending

    Increased Healthcare Spending

    • Significant rise in healthcare spending globally.
    • Example: In the U.S., healthcare spending increased by 9.7% in 2022 to $4.1 trillion.

    Economic Benefits of Vaccination

    • Assessing the full social and economic benefits of vaccination is crucial.
    • New vaccine generations often come with higher costs, necessitating a comprehensive evaluation of their value.

    Major Companies in the Market

    • Pfizer Inc.
    • Johnson & Johnson Services Inc.
    • Sinopharm Group Co Ltd.
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A.
    • AstraZeneca PLC
    • GlaxoSmithKline PLC
    • Takeda Pharmaceutical Company Limited
    • Baxter International Inc.

    Pfizer’s Comprehensive Meningococcal Vaccine

    • FDA Approval: Pfizer’s PENBRAYA vaccine received FDA approval in October 2023.
    • Coverage: PENBRAYA protects against serogroups A, B, C, W, and Y.
    • Clinical Trials: Demonstrated non-inferior immunogenicity and favorable safety compared to existing vaccines.

    Strategic Acquisitions

    GlaxoSmithKline’s Acquisition of Affinivax

    • Acquisition Details: GSK acquired Affinivax Inc. for $3.3 billion in August 2022.
    • Objective: Strengthening GSK’s portfolio in specialty medicines and vaccines.
    • Affinivax’s Role: A next-generation vaccine technology company contributing to the meningococcal vaccines market.

    Market Segmentation

    1. By Vaccine Type:
      • Meningococcal Conjugate Vaccine
      • Polysaccharide Vaccine
      • Subcapsular Vaccine
    2. By Serotype:
      • Men ACWY
      • Men B/Bc
      • Men C
    3. By Age Group:
      • Infants
      • Children
      • Adolescents and Young Adults
      • Adults
    4. By Distribution Channel:
      • Pharmacies
      • Community Clinics
      • Public Health Agencies
      • Other Channels
    5. By End User:
      • Hospitals
      • Research
      • Academic Institutes

    Regional Insights

    • North America: The largest region in the meningococcal vaccines market in 2023.
    • Asia-Pacific: Expected to be the fastest-growing region during the forecast period.

    The meningococcal vaccines market is poised for significant growth, driven by advancements in healthcare, emerging disease strains, and strategic industry initiatives. As new trends and technologies emerge, the market will continue to evolve, ensuring better protection against meningococcal diseases worldwide.

    Request for A Sample Of The Global Meningococcal Vaccines Market Report:
    https://www.thebusinessresearchcompany.com/sample_request?id=8013&type=smp